Cell catalogues

  • The EBiSC catalogue

    The on-line catalogue of induced Pluripotent Stem Cells (iPSCs) is available to academic and commercial scientists for use in disease modelling and other forms of pre-clinical research. The initial collection of iPSCs available from the catalogue have been generated from a wide range of donors representing either specific disease backgrounds or healthy control donors.

    Read more »
  • hPSCreg® – European Human Pluripotent Stem Cell Registry

    hPSCreg® is a freely accessible global registry for human pluripotent stem cell lines (hPSC-lines). The registry allows searching for cell lines and for information available about these cell lines. New cell lines can be registered and information to already registered cell lines can be added. hPSCreg® is an open platform for coordination and cooperation in the area of hPSC research and application, to avoid redundancy and ensuring comparable quality standards in hPSC research. hPSCreg® aims to collaborate with registries and cell banks worldwide.

    Read more »

EBiSC supporting entities in project phases 1 & 2

  • Innovative Medicines Initiative (IMI)

    The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

    Read more »
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)

    EFPIA brings together 33 European national pharmaceutical industry associations as well as 40 leading companies undertaking research, development and the manufacture in Europe of medicinal products for human use.

    Read more »
  • European Commission (EC)

    EU funding and support helps health researchers to find new ways of preventing diseases, developing better diagnostics and more effective therapies, and taking up new models of care and technologies promoting health and wellbeing.

    Read more »

Other related projects & research programmes

  • StemBANCC – Stem cells for biological assays of novel drugs and predictive toxicology (IMI project)

    StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

    Read more »
  • EU-AIMS - European Autism Interventions - a Multicentre Study for Developing New Medications

    EU-AIMS is the largest single grant for autism in the world, and the largest for the study of any mental health disorder in Europe. EU-AIMS involves a novel collaboration between organisations representing affected individuals and their families (Autism Speaks), academia and industry who for the first time in the world have come together to develop the infrastructure underpinning new treatments for autism. Patient organizations, academia and industry join forces to develop and assess novel treatment approaches for autism.

    Read more »
  • HipSci - Human Induced Pluripotent Stem Cells Initiative

    HipSci brings together diverse constitutents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPSC resource and use it to carry out cellular genetic studies.

    Read more »
  • SCR&Tox – Stem cells for relevant efficient extended and normalized toxicology

    SCR&Tox aims to develop methods to predict the toxicity of drugs and cosmetics _in tissues derived from pluripotent stem cells. “We will measure if cellular pathways within tissues are altered by chronic exposure to these products, focusing on five organs: the liver, heart, skin, nervous system and musculoskeletal system.

    Read more »
  • MIP-DILI – Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury

    Drug Induced Liver Injury is a major health problem with broad implications for patients, health care professionals, the pharmaceutical industry and drug regulatory agencies. The current test systems employed by the pharmaceutical industry are poorly predictive for DILI. The Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury (MIP-DILI) project will address this situation by the development of innovative preclinical test systems.

    Read more »